ARWR
Arrowhead Pharmaceuticals Inc.

12,382
Mkt Cap
$8.38B
Volume
1.03M
52W High
$76.76
52W Low
$9.57
PE Ratio
38.89
ARWR Fundamentals
Price
$58.62
Prev Close
$59.82
Open
$58.20
50D MA
$65.78
Beta
1.53
Avg. Volume
3.65M
EPS (Annual)
-$0.0122
P/B
14.46
Rev/Employee
$1.17M
$4,464.99
Loading...
Loading...
News
all
press releases
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Citigroup Inc.
Citigroup Inc. decreased its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 63.4% during the 3rd quarter, according to its most recent filing with the Securities...
MarketBeat·10h ago
News Placeholder
More News
News Placeholder
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Intech Investment Management LLC
Intech Investment Management LLC cut its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 39.9% during the third quarter, according to its most recent Form 13F filing with...
MarketBeat·2d ago
News Placeholder
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Down 8% - What's Next?
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Down 8% - What's Next...
MarketBeat·3d ago
News Placeholder
Arrowhead Pharmaceuticals Teases 2026 Catalysts, Waylivra Launch Momentum at TD Cowen Conference
Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives outlined a busy slate of clinical catalysts and a growing commercial footprint during a presentation at TD Cowen's 46th Annual Healthcare...
MarketBeat·5d ago
News Placeholder
Erste Asset Management GmbH Has $2.47 Million Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR
Erste Asset Management GmbH boosted its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 55.3% in the third quarter, according to the company in its most recent filing with the...
MarketBeat·8d ago
News Placeholder
Arrowhead Pharmaceuticals, Inc. $ARWR Position Increased by JPMorgan Chase & Co.
JPMorgan Chase & Co. raised its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 90.3% during the third quarter, according to its most recent Form 13F filing with the...
MarketBeat·8d ago
News Placeholder
Sarepta Q4 Loss Wider Than Expected, Sales Beat Estimates
SRPT posts a wider Q4 loss as Elevidys sales tumble, but revenues top estimates and 2026 guidance outlines a cautious recovery path.
Zacks·11d ago
News Placeholder
Vanguard Group Inc. Has $553.08 Million Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR
Vanguard Group Inc. lifted its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 3.3% during the 3rd quarter, according to its most recent filing with the Securities and...
MarketBeat·12d ago
News Placeholder
Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: TD Cowen 46th Annual Health Care Conference March 2-4, 2026 Type...
Business Wire·13d ago
News Placeholder
Arrowhead Pharmaceuticals, Inc. $ARWR Stock Position Raised by King Luther Capital Management Corp
King Luther Capital Management Corp increased its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 54.7% during the 3rd quarter, according to the company in its...
MarketBeat·16d ago
<
1
2
...
>

Latest ARWR News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.